AngioSoma, Inc. to upgrade its OmniCath Patents into OmniCath 2 Atherectomy Catheter

MONTGOMERY, TEXAS (Business Wire, November 4, 2016 at 9:36 AM CST) – AngioSoma, Inc. today announces that it was filing new improvements to its US Patent No. 5,728,129 and five predecessor patents 4,850,957; 4,994,067; 5,087,265; and 5,695,519; all of which will be used as “prior art” to the its newest catheter, the OmniCath® II.  With the new improvements being added, the OmniCath® II may be the most versatile debulking and vessel remodeling atherectomy catheter available for endovascular interventional procedures in treating coronary and peripheral artery diseases resulting in plaque-atherosclerosis.  The new improvements include:

  • a plaque cutting mechanism that allows cutting from either (a) the end-tip to first recanalize the blocked lumen, then (b) a further step of complete debulking the lesion using the directional side-window;
  • discrete angioplasty balloon proximal (upstream) to blood flow allowing for second step angioplasty and vessel wall remolding;
  • using the same balloon for optional upstream blocking of blood flow allowing simultaneous saline irrigation and clear endoscopic view from the side-cutting window or most distal tip, or for video feed giving the operator/physician precise visual control; and
  • completely detachable and disposable catheter shaft, driveline, cutter, and angioplasty balloon from motor assembly preventing cross contamination of infections such as MRSA while allowing reuse of its lithium battery powered motor.

Per CEO Alexanderia K. Blankenship, “The OmniCath 2 will be priced competitively with both balloon catheters and atherectomy devices providing physicians with a multiplicity of easy options.”  The company estimates that it may be able to achieve sales of over $1 billion annually when fully integrated into the market.


AngioSoma, Inc. ( is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD‘).  Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA‘) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.


This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.


AngioSoma, Inc.
Alex Blankenship
(832) 781 – 8521

© 2016 by AngioSoma, Inc., all rights reserved. Original press release at BusinessWire at